Treatment resistance in stem cells and breast cancer

Journal of Mammary Gland Biology and Neoplasia

Volumn 14, Issue 1, 2009, Pages 79-82

  Dave, Bhuvanesh ^a   Chang, Jenny ^a  

^a BAYLOR COLLEGE OF MEDICINE   (United States)

Author keywords

Breast; Cancer stem cells; Clinical trials; Resistance; Therapy

Indexed keywords

ALDEHYDE DEHYDROGENASE; CD24 ANTIGEN; HERMES ANTIGEN; LAPATINIB;

BREAST CANCER; CANCER REGRESSION; CANCER RELAPSE; CANCER RESISTANCE; CANCER STEM CELL; CELL DIFFERENTIATION; CELL RENEWAL; HUMAN; NONHUMAN; ONCOGENE; RADIOSENSITIVITY; REVIEW; TUMOR REGRESSION;

ANIMALS; BREAST NEOPLASMS; CLINICAL TRIALS AS TOPIC; DRUG RESISTANCE, NEOPLASM; HUMANS; NEOPLASTIC STEM CELLS;

EID: 62549093491     PISSN: 10833021     EISSN: None     Source Type: Journal    
DOI: 10.1007/s10911-009-9117-9     Document Type: Review

References (12)

1. Nowell PC. The clonal evolution of tumor cell populations. Science 1976;194(4260):23-8. doi: 10.1126/science.959840.
2. Hanahan D, Weinberg RA. The hallmarks of cancer. Cell 2000;100(1):57-70. doi: 10.1016/S0092-8674(00)81683-9.
3. Al-Hajj M, Wicha MS, Benito-Hernandez A, Morrison SJ, Clarke MF. Prospective identification of tumorigenic breast cancer cells. Proc Natl Acad Sci U S A 2003;100(7):3983-8. doi: 10.1073/pnas.0530291100.
4. Ponti D, Costa A, Zaffaroni N, Pratesi G, Petrangolini G, Coradini D, et al. Isolation and in vitro propagation of tumorigenic breast cancer cells with stem/progenitor cell properties. Cancer Res 2005;65(13):5506-11. doi: 10.1158/0008-5472.CAN-05-0626.
5. Chang JC, Wooten EC, Tsimelzon A, Hilsenbeck SG, Gutierrez MC, Tham YL, et al. Patterns of resistance and incomplete response to docetaxel by gene expression profiling in breast cancer patients. J Clin Oncol 2005;23(6):1169-77. doi: 10.1200/JCO.2005.03.156.
6. Li X, Lewis MT, Huang J, Gutierrez C, Osborne CK, Wu MF, et al. Intrinsic resistance of tumorigenic breast cancer cells to chemotherapy. J Natl Cancer Inst 2008;100(9):672-9. doi: 10.1093/jnci/djn123.
7. Yu F, Yao H, Zhu P, Zhang X, Pan Q, Gong C, et al. let-7 regulates self renewal and tumorigenicity of breast cancer cells. Cell 2007;131(6):1109-23. doi: 10.1016/j.cell.2007.10.054.
8. Brekelmans CT, Tilanus-Linthorst MM, Seynaeve C, vd Ouweland A, Menke-Pluymers MB, Bartels CC, et al. Tumour characteristics, survival and prognostic factors of hereditary breast cancer from BRCA2-, BRCA1- and non-BRCA1/2 families as compared to sporadic breast cancer cases. Eur J Cancer 2007;43(5):867-76. doi: 10.1016/j.ejca.2006.12.009.
9. Ginestier C, Hur MH, Charafe-Jauffret E, Monville F, Dutcher J, Brown M, et al. ALDH1 is a marker of normal and malignant human mammary stem cells and a predictor of poor clinical outcome. Cell Stem Cell 2007;1(5):555-67. doi: 10.1016/j.stem.2007.08.014.
10. Honeth G, Bendahl PO, Ringner M, Saal LH, Gruvberger-Saal SK, Lovgren K, et al. The CD44+/CD24-phenotype is enriched in basal-like breast tumors. Breast Cancer Res 2008;10(3):R53. doi: 10.1186/bcr2108.
11. Krop IE, Kosh M, Fearen I, Savoie J, Dallob A, Matthews C, Stone J, Winer E, Freedman SJ, Lorusso P. Phase I pharmacokinetic (PK), and pharmacodynamic (PD) trial of the novel oral Notch inhibitor MK-0752 in patients (pts) with advanced breast cancer (BC) and other solid tumors. Journal of Clinical Oncology, 2006 ASCO Annual Meeting. Proceedings Part I. Vol 24, No. 18S (June 20 Supplement), 2006: 10574.
12. LoRusso PM, Rudin CM, Borad MJ, Vernillet L, Darbonne WC, Mackey H, DiMartino JF, de Sauvage F, Low JA, Von Hoff DD. A first-in-human, first-in-class, phase (ph) I study of systemic Hedgehog (Hh) pathway antagonist, GDC-0449, in patients (pts) with advanced solid tumors. J Clin Oncol 26: 2008 (May 20 suppl; abstr 3516.